Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Brubaker opened the second quarter with a basket, but Cameron Vickers scored four straight for the Indians to make it a 20-18 ...

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

New York, United States - September 05, 2024 Demonstrators protest against Gilead Pharmaceuticals in midtown Manhattan.

• Northmor at East Knox, boys’ basketball, 4:30 p.m. • Danville at Cardington, boys’ basketball, 6 p.m. • Centerburg at Mount Gilead, boys’ basketball, 6 p.m. • Mount Gilead at New Albany, boys’ ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

University of Utah Health announced Friday the development of a promising new HIV drug. The drug, lenacapavir, has been named ...

The Centerburg Trojans delivered a commanding performance on December 10, cruising to a 45-7 victory over Mt. Gilead in a ...